(Total Views: 59)
Posted On: 02/16/2021 3:05:49 PM
Post# of 74551

$NK News Article - ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate https://marketwirenews.com/news-releases/immu...54750.html


My Twitter: WhyteStocks